Company news

Enliven Therapeutics, Inc. news in 2020

Enliven Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition

December 6, 2020

Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition

November 29, 2020

Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory

November 16, 2020

Imara Reports Third Quarter 2020 Financial Results and Business Highlights

November 4, 2020

Imara to Webcast Conference Call of Third Quarter Financial Results

October 28, 2020

Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia

October 15, 2020

Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease

August 24, 2020

Imara Reports Second Quarter 2020 Financial Results and Business Highlights

August 13, 2020

Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease

August 12, 2020

Imara to Webcast Conference Call of Second Quarter 2020 Financial Results

August 6, 2020

Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia

July 29, 2020

Imara Added to Membership of U.S. Small-Cap Russell 2000® Index

June 28, 2020

Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia

June 23, 2020

Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress

June 11, 2020

Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress

May 20, 2020

Imara Reports First Quarter 2020 Financial Results and Business Highlights

May 6, 2020

Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders

May 5, 2020

Imara Announces Appointment of Stephen M. Migausky as General Counsel

May 3, 2020

Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.

April 22, 2020

IMARA Announces Pricing of Initial Public Offering

March 10, 2020

Calls in 2020